GoldenGolden
Immunomic Therapeutics

Immunomic Therapeutics

A biotechnology company developing nucleic acid immunotherapy platform and protein based vaccines

Immunomic Therapeutics is a company that looks to develop biotechnologies through an immunotherapy platform. The company was founded in 2005, in Rockville, Maryland, United States.

The company studies investigational technologies that can assist in altering how immunotherapy solutions are utilized across a range of diseases. They work with solutions for cancer, allergies, and infectious diseases. The company studies nucleic acid immunotherapy platforms to change how immunotherapies are used for cancer and other uses.

Immunomic Therapeutics is developing treatments such as their ITI-1000 and ITI-1001 for GBM, ITI-2000 for HPV and tumors, ITI-3000 for Merkel Cell Carcinoma, ITI-4000 for NPC and Gastic issues, ITI-5000 for Neoantigens, ITI-6000 for HCC, ITI-7000 for bladder infections, and their ITI-COVID-19 for SARS-CoV-2. They have partnered with entities such as PharmaJet, Zenoq, and Replicate.

They have also created a platform called UNITE (Universal Intracellular Targeted Expression). The platform has lysosomal targeting technology, use adjuvants, antigen selection and optimizations, and offer various delivery methods.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Immunomic Therapeutics funding round, March 2010
600,000
March 28, 2010
2 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Bernie Rudnick

Investor

Brian Gaister

Investor

Colin Magowan

Investor

Daniel Geselowitz

Investor

David Manlove

Investor

Edwin Blewett

Investor

Franco Pissani

Employee

Gary Zebrowski

Investor

Howard Lubert

Investor

Ira Wallace

Investor

Ira Wallace

Investor

James G. W. Reed Sr.

Investor

Jason Bell

Investor

Kal Vepuri

Advisor

Kal Vepuri

Investor

Lisa Salley

Investor

Pushkar Vartak

Employee

Pushkar Vartak

Employee

Ryan Thompson

Investor

Sambida Pradhan

Employee

Sherry Zins Calvert

Investor

Stephen M. Nagler

Investor

Steven Nemerson, MD, MSE, MBA

Investor

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
April 20, 2021
BioSpace
Lineage Announces Worldwide License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC Platform - read this article along with other careers information, tips and advice on BioSpace
DelveInsight Business Research, LLP
March 10, 2021
www.prnewswire.com:443
/PRNewswire/ -- DelveInsight's Brain Tumor Market Report proffers an all-encompassing view of the market trends, key pharmaceutical companies working in the...
DelveInsight Business Research, LLP
March 4, 2021
www.prnewswire.com:443
/PRNewswire/ -- Rare cancers account for approximately 22% of all the diagnosed cancer cases. The US National Cancer Institute defines rare cancers as those...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.